Drug Profile
Research programme: therapeutics for neuromuscular disorders - NMD Pharma
Alternative Names: CLC-1 inhibitors - NMD PharmaLatest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator NMD Pharma
- Class Small molecules
- Mechanism of Action CLC-1-channel-antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neuromuscular disorders